| Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP). In addition, the company is developing givosiran for the treatment of patients with AHP; lumasiran for the treatment of primary hyperoxaluria type 1, or PH1; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; and vutrisiran for the treatment of ATTR amyloidosis. Alnylam Pharmaceuticals, Inc. has strategic alliances primarily with Sanofi Genzyme; The Medicines Company; Ionis Pharmaceuticals, Inc.; and Regeneron Pharmaceuticals, Inc., as well as collaboration with Vir Biotechnology, Inc. to advance RNAi therapeutics for the treatment of coronavirus infection, including COVID-19. It also has a collaboration and license agreement with Dicerna Pharmaceuticals, Inc. to develop and commercialize investigational ribonucleic acid interference therapeutics for the treatment of alpha-1 antitrypsin deficiency-associated liver disease, as well as Vir Biotechnology, Inc. to develop and commercialize RNAi therapeutics. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. |
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Greenstreet Yvonne | Chief Operating Officer | Jul 09 | Option Exercise | 43.14 | 11,236 | 484,743 | 16,056 | Jul 10 04:03 PM | | Greenstreet Yvonne | Chief Operating Officer | Jul 09 | Sale | 161.00 | 11,236 | 1,808,996 | 4,820 | Jul 10 04:03 PM | | Greene Barry E | President | Jul 07 | Option Exercise | 9.14 | 22,265 | 203,502 | 84,501 | Jul 09 04:02 PM | | Greene Barry E | President | Jul 07 | Sale | 159.99 | 22,265 | 3,562,177 | 62,236 | Jul 09 04:02 PM | | Vaishnaw Akshay | President, R&D | Jun 22 | Option Exercise | 42.22 | 970 | 40,953 | 15,089 | Jun 24 04:02 PM | | Vaishnaw Akshay | President, R&D | Jun 22 | Sale | 151.07 | 970 | 146,536 | 14,119 | Jun 24 04:02 PM | | MARAGANORE JOHN | Chief Executive Officer | May 20 | Option Exercise | 9.14 | 34,765 | 317,752 | 232,354 | May 22 04:03 PM | | MARAGANORE JOHN | Chief Executive Officer | May 20 | Sale | 143.22 | 34,765 | 4,978,983 | 197,589 | May 22 04:03 PM | | Greenstreet Yvonne | Chief Operating Officer | May 06 | Option Exercise | 77.10 | 50,000 | 3,855,000 | 54,820 | May 07 04:08 PM | | Greene Barry E | President | May 06 | Option Exercise | 9.14 | 22,265 | 203,502 | 84,501 | May 07 04:09 PM | | Greene Barry E | President | May 06 | Sale | 149.99 | 22,265 | 3,339,527 | 62,236 | May 07 04:09 PM | | Greenstreet Yvonne | Chief Operating Officer | May 06 | Sale | 150.00 | 50,000 | 7,500,000 | 4,820 | May 07 04:08 PM | | Greenstreet Yvonne | Chief Operating Officer | May 05 | Option Exercise | 42.22 | 7,811 | 329,780 | 12,631 | May 07 04:08 PM | | Greenstreet Yvonne | Chief Operating Officer | May 05 | Sale | 140.00 | 7,811 | 1,093,540 | 4,820 | May 07 04:08 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Apr 20 | Option Exercise | 77.40 | 10,000 | 774,000 | 24,492 | Apr 22 04:07 PM | | Vaishnaw Akshay | President, R&D | Apr 20 | Option Exercise | 42.22 | 21,971 | 927,616 | 36,090 | Apr 22 04:06 PM | | Vaishnaw Akshay | President, R&D | Apr 20 | Sale | 140.00 | 21,971 | 3,075,940 | 14,119 | Apr 22 04:06 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Apr 20 | Sale | 139.00 | 10,000 | 1,390,000 | 14,492 | Apr 22 04:07 PM | | MARAGANORE JOHN | Chief Executive Officer | Feb 20 | Option Exercise | 9.14 | 34,765 | 317,752 | 224,758 | Feb 21 04:02 PM | | MARAGANORE JOHN | Chief Executive Officer | Feb 20 | Sale | 131.85 | 34,765 | 4,583,674 | 189,993 | Feb 21 04:02 PM | | SHARP PHILLIP A | Director | Feb 12 | Option Exercise | 12.48 | 30,000 | 374,400 | 265,633 | Feb 13 04:06 PM | | SHARP PHILLIP A | Director | Feb 12 | Sale | 130.00 | 30,000 | 3,900,000 | 235,633 | Feb 13 04:06 PM | | Greenstreet Yvonne | Chief Operating Officer | Feb 10 | Option Exercise | 42.22 | 5,600 | 236,432 | 11,808 | Feb 11 04:08 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Feb 10 | Option Exercise | 77.40 | 10,000 | 774,000 | 22,258 | Feb 12 04:03 PM | | PAUL STEVEN M | Director | Feb 10 | Option Exercise | 14.67 | 30,000 | 440,100 | 31,000 | Feb 11 04:08 PM | | PAUL STEVEN M | Director | Feb 10 | Sale | 130.00 | 30,000 | 3,900,000 | 1,000 | Feb 11 04:08 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Feb 10 | Sale | 129.00 | 10,000 | 1,290,000 | 12,258 | Feb 12 04:03 PM | | Greenstreet Yvonne | Chief Operating Officer | Feb 10 | Sale | 130.00 | 9,892 | 1,285,960 | 1,916 | Feb 11 04:08 PM | | Vaishnaw Akshay | President, R&D | Feb 07 | Option Exercise | 42.22 | 22,750 | 960,505 | 34,923 | Feb 11 04:08 PM | | Greenstreet Yvonne | Chief Operating Officer | Feb 07 | Option Exercise | 42.22 | 6,250 | 263,875 | 12,458 | Feb 11 04:08 PM | | Greenstreet Yvonne | Chief Operating Officer | Feb 07 | Sale | 123.90 | 6,250 | 774,375 | 6,208 | Feb 11 04:08 PM | | Vaishnaw Akshay | President, R&D | Feb 07 | Sale | 125.00 | 23,708 | 2,963,500 | 11,215 | Feb 11 04:08 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Jan 29 | Option Exercise | 77.40 | 6,337 | 490,484 | 14,932 | Jan 31 04:05 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Jan 29 | Sale | 119.00 | 6,337 | 754,103 | 8,595 | Jan 31 04:05 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Jan 27 | Option Exercise | 42.22 | 34,374 | 1,451,270 | 49,632 | Jan 29 04:03 PM | | KEATING LAURIE | EVP, Chief Legal Officer | Jan 27 | Sale | 117.70 | 41,037 | 4,829,970 | 8,595 | Jan 29 04:03 PM | | Greenstreet Yvonne | Chief Operating Officer | Nov 20 | Option Exercise | 42.22 | 8,404 | 354,817 | 10,320 | Nov 22 04:05 PM | | Fanucci Marsha | Director | Nov 20 | Option Exercise | 13.80 | 75,000 | 1,035,000 | 75,000 | Nov 22 04:06 PM | | Greenstreet Yvonne | Chief Operating Officer | Nov 20 | Sale | 105.00 | 8,404 | 882,420 | 1,916 | Nov 22 04:05 PM | | Fanucci Marsha | Director | Nov 20 | Sale | 100.00 | 75,000 | 7,500,000 | 0 | Nov 22 04:06 PM | | SHARP PHILLIP A | Director | Nov 18 | Option Exercise | 16.43 | 15,000 | 246,450 | 250,633 | Nov 20 04:17 PM | | SHARP PHILLIP A | Director | Nov 18 | Sale | 91.71 | 15,000 | 1,375,662 | 235,633 | Nov 20 04:17 PM | | Greene Barry E | President | Oct 22 | Option Exercise | 16.43 | 58,913 | 967,941 | 111,851 | Oct 24 04:04 PM | | Greene Barry E | President | Oct 22 | Sale | 89.99 | 58,913 | 5,301,581 | 52,938 | Oct 24 04:04 PM | | MARAGANORE JOHN | Chief Executive Officer | Oct 14 | Option Exercise | 16.43 | 49,456 | 812,562 | 239,449 | Oct 16 04:06 PM | | MARAGANORE JOHN | Chief Executive Officer | Oct 14 | Sale | 79.45 | 49,456 | 3,929,210 | 189,993 | Oct 16 04:06 PM |
|
